The following table presents a summary of the corrections to the impacted financial statement line items in the Company’s financial statements previously issued in the unaudited March 31, 2025 Quarterly Report on Form 10-Q (in thousands):


	Three Months Ended March 31, 2025
	As Previously Reported		Adjustment		As Revised
Cost of sales	$	96,080	$	4,521	$	100,601
Gross profit	220,775		(4,521)		216,254
Selling, general, and administrative	133,667		(4,521)		129,146

The following table presents a summary of the corrections to the impacted Cardiopulmonary disaggregated segment income table line items in “Note 10. Geographic and Segment Information” previously included in the unaudited March 31, 2025 Quarterly Report on Form 10-Q (in thousands):


	Three Months Ended March 31, 2025
	As Previously Reported		Adjustment		As Revised
Cost of sales	$	80,399	$	4,521	$	84,920
Selling, general, and administrative	58,480		(4,521)		53,959